Nature Communications (Nov 2022)

Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19

  • Philipe Gobeil,
  • Stéphane Pillet,
  • Iohann Boulay,
  • Nathalie Charland,
  • Aurélien Lorin,
  • Matthew P. Cheng,
  • Donald C. Vinh,
  • Philippe Boutet,
  • Robbert Van Der Most,
  • François Roman,
  • Maria Angeles Ceregido,
  • Nathalie Landry,
  • Marc-André D’Aoust,
  • Brian J. Ward

DOI
https://doi.org/10.1038/s41467-022-34728-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 10

Abstract

Read online

Here, the authors report results from a Phase 1 trial with an AS03-adjuvanted, plant-based virus-like particle displaying the spike protein of the ancestral SARS-CoV-2. Six months post-second dose, they observe good neutralizing antibody titers and T cell responses to ancestral virus and variants of concern in participants.